Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab)

Research output: Contribution to journalArticle

97 Scopus citations

Abstract

Three patients with refractory pemphigus vulgaris improved after rituximab, an anti-CD20 monoclonal antibody directed against B cells. Treatment was well tolerated immediately, but one patient developed fatal pneumocystis carinii pneumonia. Serious infections have occurred in several pemphigus patients treated with rituximab and immunosuppressive medications, warranting further evaluation of risk-benefit ratio.

Original languageEnglish (US)
Pages (from-to)817-819
Number of pages3
JournalJournal of the American Academy of Dermatology
Volume51
Issue number5
DOIs
StatePublished - Nov 1 2004

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab)'. Together they form a unique fingerprint.

  • Cite this